advertisement
Abstract #46911 Published in IGR 13-3
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: A pooled analysis of six double-masked, randomized, active-controlled clinical trials
Wirta D; van Denburgh AM; Weng E; Whitcup SM; Kurstjens S; Beddingfield III FCClinical Ophthalmology 2011; 5: 759-765
Background: Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two double-masked, active-controlled clinical trials. Four additional long-term studies ($12 months) were conducted; however, the aggregate safety profile of the six studies has not been reported. Methods: Adverse events (AEs) were pooled from six double-masked, active-controlled, long-term clinical trials in which subjects received bimatoprost 0.03% once daily (QD) or twice daily (BID) as an eyedrop. AE terms were converted to MedDRA (V.11.0) Preferred Terms and analyzed. Results: In total, 1409 patients received more than one dose of bimatoprost 0.03% QD or BID. Most AEs were mild in severity and reported by 86.7% (QD) and 94.8% (BID) of subjects (#12 months of treatment). AEs reported through month 12 (aggregate incidence of $5%) were conjunctival hyperemia, increased eyelash growth, eye pruritus, periocular skin hyperpigmen-tation, eye irritation, dry eye, and hypertrichosis. AE onset was generally reported within four months of treatment. The cumulative incidence of common AEs in the QD treatment group at 24-48 months was similar to that measured at 12 months of treatment. Conclusion: Bimatoprost 0.03% has a favorable safety and tolerability profile as characterized by six long-term studies. Common AEs were due to the known pharmacological activity of bimatoprost and reversible with treatment cessation.
D. Wirta. 1501 superior Ave, suite 303, Newport Beach, CA 92663, United States.
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
